246 related articles for article (PubMed ID: 36592300)
1. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.
Martin G
Dermatol Ther (Heidelb); 2023 Feb; 13(2):417-435. PubMed ID: 36592300
[TBL] [Abstract][Full Text] [Related]
2. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
3. Deucravacitinib: First Approval.
Hoy SM
Drugs; 2022 Nov; 82(17):1671-1679. PubMed ID: 36401743
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
6. Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.
Xu Y; Li Z; Wu S; Guo L; Jiang X
Front Immunol; 2023; 14():1180170. PubMed ID: 37334353
[TBL] [Abstract][Full Text] [Related]
7. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S; Okubo Y; Tada Y; Ohtsuki M; Colston E; Napoli A; Shao Y; Banerjee S; Morita A
J Dermatol; 2024 Mar; 51(3):365-379. PubMed ID: 38268101
[TBL] [Abstract][Full Text] [Related]
8. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
Rusiñol L; Puig L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
[TBL] [Abstract][Full Text] [Related]
9. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
10. Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
Galluzzo M; Vellucci L; Marcelli L; Paganini C; Bianchi L; Talamonti M
Expert Opin Pharmacother; 2023 Jun; 24(9):981-988. PubMed ID: 37147879
[TBL] [Abstract][Full Text] [Related]
11. Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far.
Martins A; Lé AM; Torres T
Drugs Context; 2023; 12():. PubMed ID: 37168876
[TBL] [Abstract][Full Text] [Related]
12. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.
Kingston P; Blauvelt A; Strober B; Armstrong AW
J Psoriasis Psoriatic Arthritis; 2023 Oct; 8(4):156-165. PubMed ID: 38188537
[TBL] [Abstract][Full Text] [Related]
13. Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
Truong TM; Pathak GN; Singal A; Taranto V; Rao BK
Ann Pharmacother; 2024 Apr; 58(4):416-427. PubMed ID: 37341177
[TBL] [Abstract][Full Text] [Related]
14. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
15. TYK2: an emerging therapeutic target in rheumatic disease.
Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
[TBL] [Abstract][Full Text] [Related]
16. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2021 Nov; 27(12):2023-2030. PubMed ID: 34089259
[TBL] [Abstract][Full Text] [Related]
17. Deucravacitinib in moderate-to-severe psoriasis.
Vu A; Maloney V; Gordon KB
Immunotherapy; 2022 Nov; 14(16):1279-1290. PubMed ID: 36373503
[TBL] [Abstract][Full Text] [Related]
18. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Gooderham MJ; Hong HC; Litvinov IV
Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536
[TBL] [Abstract][Full Text] [Related]
19. SOTYKTU
Gupta AK; Wang T; Vincent K; Abramovits W
Skinmed; 2023; 21(3):192-196. PubMed ID: 37634105
[TBL] [Abstract][Full Text] [Related]
20. The preclinical discovery and development of deucravacitinib for the treatment of psoriasis.
Coscarella G; Malvaso D; Mannino M; Caldarola G; Fossati B; De Simone C; Chiricozzi A; Peris K
Expert Opin Drug Discov; 2023; 18(11):1201-1208. PubMed ID: 37574849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
